A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial
Open Access
- 20 January 2022
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 26, 100892
Abstract
No abstract availableKeywords
Funding Information
- National Center for Child Health and Development
This publication has 24 references indexed in Scilit:
- Atorvastatin Safety in Kawasaki Disease Patients With Coronary Artery AneurysmsPediatric Cardiology, 2013
- Topical anti-inflammatory effect of hypocholesterolaemic drugsJournal of Pharmacy and Pharmacology, 2011
- Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritisJournal of Lipid Research, 2011
- Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cellsNaunyn-Schmiedeberg's Archives of Pharmacology, 2011
- The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki diseaseClinical and Experimental Immunology, 2011
- Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki diseaseClinical and Experimental Immunology, 2009
- Lovastatin Inhibits TGF-β–Induced Myofibroblast Transdifferentiation in Human Tenon FibroblastsInvestigative Ophthalmology & Visual Science, 2008
- Tumor necrosis factor ? induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatinCardiovascular Research, 2004
- Kawasaki syndromeThe Lancet, 2004
- ERK1/2 mediates TNF‐α‐induced matrix metalloproteinase‐9 expression in human vascular smooth muscle cells via the regulation of NF‐κB and AP‐1: Involvement of the ras dependent pathwayJournal of Cellular Physiology, 2003